Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.9748 SEK
−388.17 M SEK
238.73 M SEK
1.04 B
About XBRANE BIOPHARMA AB
Sector
CEO
Martin Åmark
Headquarters
Solna
Website
Founded
2008
ISIN
SE0007789409
FIGI
BBG00BV3XZL7
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. Its products include Ximluci, BIIB801, Xdivane, Xtrudane, and Xdarzane. The company was founded by Jan-Willem de Gier, Marten Hellberg, and Samuel Wagner in 2008 and is headquartered in Solna, Sweden.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of XBRANE is 0.1926 SEK — it has decreased by −2.73% in the past 24 hours. Watch XBRANE BIOPHARMA AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange XBRANE BIOPHARMA AB stocks are traded under the ticker XBRANE.
XBRANE stock has fallen by −0.62% compared to the previous week, the month change is a −7.40% fall, over the last year XBRANE BIOPHARMA AB has showed a −98.94% decrease.
We've gathered analysts' opinions on XBRANE BIOPHARMA AB future price: according to them, XBRANE price has a max estimate of 0.60 SEK and a min estimate of 0.30 SEK. Watch XBRANE chart and read a more detailed XBRANE BIOPHARMA AB stock forecast: see what analysts think of XBRANE BIOPHARMA AB and suggest that you do with its stocks.
XBRANE reached its all-time high on Jun 28, 2021 with the price of 180.4000 SEK, and its all-time low was 0.1262 SEK and was reached on Sep 10, 2024. View more price dynamics on XBRANE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
XBRANE stock is 6.35% volatile and has beta coefficient of 2.66. Track XBRANE BIOPHARMA AB stock price on the chart and check out the list of the most volatile stocks — is XBRANE BIOPHARMA AB there?
Today XBRANE BIOPHARMA AB has the market capitalization of 294.58 M, it has decreased by −2.22% over the last week.
Yes, you can track XBRANE BIOPHARMA AB financials in yearly and quarterly reports right on TradingView.
XBRANE BIOPHARMA AB is going to release the next earnings report on Feb 21, 2025. Keep track of upcoming events with our Earnings Calendar.
XBRANE earnings for the last quarter are −0.03 SEK per share, whereas the estimation was 0.00 SEK resulting in a −547.61% surprise. The estimated earnings for the next quarter are 0.01 SEK per share. See more details about XBRANE BIOPHARMA AB earnings.
XBRANE BIOPHARMA AB revenue for the last quarter amounts to 69.50 M SEK, despite the estimated figure of 111.50 M SEK. In the next quarter, revenue is expected to reach 176.20 M SEK.
XBRANE net income for the last quarter is −45.12 M SEK, while the quarter before that showed −70.50 M SEK of net income which accounts for 36.01% change. Track more XBRANE BIOPHARMA AB financial stats to get the full picture.
No, XBRANE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 93.00 employees. See our rating of the largest employees — is XBRANE BIOPHARMA AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XBRANE BIOPHARMA AB EBITDA is −226.48 M SEK, and current EBITDA margin is −121.05%. See more stats in XBRANE BIOPHARMA AB financial statements.
Like other stocks, XBRANE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XBRANE BIOPHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XBRANE BIOPHARMA AB technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XBRANE BIOPHARMA AB stock shows the sell signal. See more of XBRANE BIOPHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.